Eric Benevich joins Neurocrine Biosciences as Chief Commercial Officer

He was most recently Vice President of Marketing at Avanir Pharmaceuticals

Neurocrine Biosciences, a US developer of pharmaceuticals for neurological and endocrine-based diseases, says Eric Benevich has joined the company as Chief Commercial Officer.

Benevich was most recently at Avanir Pharmaceuticals as Vice President of Marketing, where he was responsible for Nuedextra and commercialisation of their CNS pipeline. He has more than 20 years of experience in the pharmaceutical industry with Peninsula Pharmaceuticals, Amgen and AstraZeneca.

You may also like

Regulatory

Tardive dyskinesia – valbenazine

There are currently no approved treatments for tardive dyskinesia, and the symptoms are frequently irreversible
Research & Development

Drug licensing deals in 2010

Big pharma companies have been busy filling the yawning gaps in their product pipelines by licensing drugs developed by smaller biotechnology firms. Dr Sarah Houlton outlines a selection of the deals done this year
Manufacturing

Lonza opens capsule drug development-focused site at its Colmar facility

The new addition to the French site will allow customers access to experts and technologies ideal for capsule formulation and development
Research & Development

Adenosine A2a receptor: novel biophysical fragment screening using polymer-encapsulated nanodiscs

Fragment screening is a useful method for hit identification as it offers an efficient and flexible way to identify novel therapeutic starting points that other techniques may have missed because of the small molecular size of the fragments
Research & Development

Roche's antiviral Xofluza reduces flu transmission in Phase III trial

Topline results suggest that Xofluza could be used to reduce the transmission of seasonal influenza
Research & Development

RSSL opens 3D imaging and metrology laboratory for end-to-end research and analysis

The laboratory will offer, micro-CT, microscopy and spectroscopy services for its pharmaceutical and medical device partners
Manufacturing

Ensuring cGMP compliance in cell and gene therapy manufacturing

3P discusses how companies can scale up their CGT manufacturing protocols while remaining compliant with stringent global regulations
Subscribe now